ClinicalTrials.gg

Program

pucotenlimab

Also written as “HX008”, “MRG003+HX008” and “MRG003 + Pucotenlimab”.

Its studies are mostly in Melanoma · Nasopharyngeal Carcinoma · Colorectal Neoplasms · Gastrointestinal Neoplasms · Triple Negative Breast Neoplasms, led by 4 companies.

Furthest: phase 3, since Jul 22, 202015 company-led studies, 6 open or runningNext primary completion: Aug 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Taizhou Hanzhong biomedical102 open or runningphase 3since Jul 22, 2020Jul 22, 2020none ahead
Binhui Biopharmaceutical22 open or runningphase 2since Feb 28, 2019Feb 28, 2019none ahead
Lepu Biopharma22 open or runningphase 3since May 8, 2025Jan 6, 2023Aug 2027phase 2 · NCT05688605
Shanghai Miracogen10 open or runningphase 2since Apr 15, 2022Apr 15, 2022none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Feb 28, 2019First study: phase 2 study in Gastrointestinal NeoplasmsNew to Binhui BiopharmaceuticalBinhui Biopharmaceutical · NCT03866525 · 300 planned · China
  2. Jul 22, 2020Taizhou Hanzhong biomedical's first study: phase 3 study in Stomach NeoplasmsNew to Taizhou Hanzhong biomedicalTaizhou Hanzhong biomedical · NCT04486651 · 560 enrolled · China
  3. Aug 31, 2020Phase 2 study in MelanomaBinhui Biopharmaceutical · NCT04616443 · 60 planned · China
  4. Sep 29, 2020Phase 2 study in Thyroid Carcinoma, AnaplasticTaizhou Hanzhong biomedical · NCT04574817 · 66 enrolled · China
  5. Jan 31, 2021Phase 2 study in Urinary Bladder NeoplasmsTaizhou Hanzhong biomedical · NCT04738630 · 110 enrolled · China
  6. Feb 2, 20213 phase 2 studiesTaizhou Hanzhong biomedical · NCT04741165, NCT04749485, NCT04750382
  7. Feb 3, 2021Phase 3 study in Nonsquamous Non-small Cell Lung CancerTaizhou Hanzhong biomedical · NCT04750083 · 700 enrolled · China
  8. Mar 28, 2021Phase 1 study in Advanced Solid TumorTaizhou Hanzhong biomedical · NCT04825392 · 30 enrolled · China
  9. Apr 15, 2022Shanghai Miracogen's first study: phase 2 study in Advanced Malignant Solid TumorsNew to Shanghai MiracogenShanghai Miracogen · NCT05338957 · 30 enrolled · China
  10. Nov 26, 20222 phase 3 studiesTaizhou Hanzhong biomedical · NCT05652894, NCT05647954
  11. Jan 6, 2023Lepu Biopharma's first study: phase 2 study in Advanced Solid TumorsNew to Lepu BiopharmaLepu Biopharma · NCT05688605 · 18 planned · China
  12. May 8, 2025Phase 3 study in RecurrenceLepu Biopharma · NCT06976190 · 446 planned · China

Ahead

  1. Aug 2027Primary completion: phase 2 study in Advanced Solid TumorsLepu Biopharma · NCT05688605
  2. May 2029Primary completion: phase 3 study in RecurrenceLepu Biopharma · NCT06976190

TargetBeta

PDCD1 →read by rule
“A recombinant human monoclonal antibody directed against the negative immunoregulatory human cell receptor programmed cell death protein 1 (PD-1; PDCD1; CD279), ”NCIt, by rule
“Programmed cell death protein 1 inhibitor”ChEMBL 37, by rule

Other programs on PDCD1

ProgramCompanyFurthest phaseStudies
ivonescimabruleAkesophase 348
rilvegostomigAstraZenecaphase 324
Iparomlimab/TuvonralimabruleQilu Pharmaceuticalphase 322
volrustomigAstraZenecaphase 319
tivunatamigPfizerphase 315
nilvanstomigruleSuzhou Zelgen Biopharmaceuticalsphase 315
enlonstobartruleCSPC Pharmaceutical Groupphase 315
ezabenlimabBoehringer Ingelheimphase 313
Anti-PD-1/IL-2 Bispecific Antibody Fusion Protein IBI363ruleInnovent Biologicsphase 310
rulonilimabruleLunan Pharmaceutical Groupphase 39
Anti-PD-1/Anti-TGF-beta Bifunctional Fusion Protein TQB2868Sino Biopharmaceuticalphase 34
sasanlimabPfizerphase 34

Studies

All 15 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT06976190Recurrence · China3RecruitingLepu BiopharmaMay 2029446
NCT05688605Advanced Solid Tumors · China2RecruitingLepu BiopharmaAug 202718
NCT05647954Melanoma Neuroendocrine Tumors Neuroectodermal Tumors Neoplasms Germ Cell and Embryonal Neoplasms by Histologic Type Neoplasms Neoplasms · China3Not yet recruitingTaizhou Hanzhong biomedicalDec 30, 2024350
NCT05652894Colorectal Neoplasms · China3Active, not recruitingTaizhou Hanzhong biomedicalJun 30, 2026190
NCT05338957Advanced Malignant Solid Tumors · China2UNKNOWNShanghai MiracogenJun 202430
NCT04825392Advanced Solid Tumor · China1UNKNOWNTaizhou Hanzhong biomedicalMay 30, 202130
NCT04750382Triple Negative Breast Neoplasms · China2UNKNOWNTaizhou Hanzhong biomedicalDec 1, 202031
NCT04749485Melanoma · China2UNKNOWNTaizhou Hanzhong biomedicalAug 19, 2020119
NCT04750083Nonsquamous Non-small Cell Lung Cancer · China3UNKNOWNTaizhou Hanzhong biomedicalSep 25, 2022700
NCT04741165Carcinoma, Hepatocellular · China2UNKNOWNTaizhou Hanzhong biomedicalApr 30, 202272
NCT04738630Urinary Bladder Neoplasms · China2UNKNOWNTaizhou Hanzhong biomedicalDec 1, 2022110
NCT04574817Thyroid Carcinoma, Anaplastic · China2UNKNOWNTaizhou Hanzhong biomedicalMay 30, 202266
NCT04616443Melanoma · China2RecruitingBinhui BiopharmaceuticalNov 30, 202560
NCT04486651Stomach Neoplasms · China3UNKNOWNTaizhou Hanzhong biomedicalAug 10, 2023560
NCT03866525Gastrointestinal Neoplasms · China2RecruitingBinhui BiopharmaceuticalAug 30, 2025300

How it is read

Names in the registry

  • “HX008”, 7 entries
  • “MRG003+HX008”, 1 entry
  • “MRG003 + Pucotenlimab”, 1 entry
  • “HX008(Pucotenlimab)”, 1 entry
  • “HX008 injection”, 1 entry

Codes read as this program: HX008.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.